UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/582,163	03/05/2007	Michal Eisenbach-Schwartz	EIS-SCHWARTZ38	1851
1444 Browdy and Ne	7590 03/16/201 imark, PLLC	EXAMINER		
1625 K Street, N.W. Suite 1100			BALLARD, KIMBERLY	
Washington, DO	C 20006		ART UNIT	PAPER NUMBER
_			1649	
			MAIL DATE	DELIVERY MODE
			03/16/2011	PAPER

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)	
	10/582,163	EISENBACH-SCHWARTZ ET AL.	
Office Action Summary	Examiner	Art Unit	
	KIMBERLY A. BALLARD	1649	
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the	correspondence address	
A SHORTENED STATUTORY PERIOD FOR REPL' WHICHEVER IS LONGER, FROM THE MAILING D  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be will apply and will expire SIX (6) MONTHS from the course the application to become ABANDOI	ON. timely filed om the mailing date of this communication. NED (35 U.S.C. § 133).	
Status			
1) ☐ Responsive to communication(s) filed on <u>03 M</u> 2a) ☐ This action is <b>FINAL</b> . 2b) ☐ This 3) ☐ Since this application is in condition for allowa closed in accordance with the practice under M	s action is non-final. nce except for formal matters, p		
Disposition of Claims			
4) Claim(s) 39-55 is/are pending in the applicatio 4a) Of the above claim(s) is/are withdra  5) Claim(s) is/are allowed.  6) Claim(s) is/are rejected.  7) Claim(s) is/are objected to.  8) Claim(s) 39-55 are subject to restriction and/or	wn from consideration.		
Application Papers			
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Example 11.	epted or b) objected to by the drawing(s) be held in abeyance. Stion is required if the drawing(s) is a	See 37 CFR 1.85(a). objected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	ts have been received. ts have been received in Applica rity documents have been recei u (PCT Rule 17.2(a)).	ation No ived in this National Stage	
Attachment(s)			
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summa Paper No(s)/Mail 5) Notice of Informa 6) Other:	Date	

Art Unit: 1649

### **DETAILED ACTION**

#### Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 41, 42, 46, 48, 52-55 in full and each of claims 39, 40, 44, 45, 47 and 49-51 in part, drawn to a method for the treatment of a psychiatric disorder, disease or condition, comprising administering Copolymer 1, or a Copolymer 1-related peptide or polypeptide thereof.

Group II, claim(s) 43 in full and each of claims 39, 40, 44, 45, 47 and 49-51 in part, drawn to a method for the treatment of a psychiatric disorder, disease or condition, comprising administering T cells activated with Copolymer 1, a Copolymer 1-related peptide or Copolymer 1-related polypeptide.

The groups of inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The first recited technical feature appears to be a method of treating an individual having a psychiatric disorder, disease or condition comprising administering Copolymer 1. However, Schwartz (*Cell Mol Neurobiol.* 2001; 21(6):617-627; listed on IDS) teaches that Copolymer 1 (Cop-1) may be used to treat chronic neurodegenerative disorders such as Alzheimer's disease (AD), which meets the limitation of a psychiatric condition according to the present invention in that AD is characterized as a memory loss disorder with cognitive impairment. Thus, the technical feature of Group I does not constitute a

special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art.

## Election of Species

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

## Psychiatric Disorders

- i) anxiety disorders as in claims 45 and 46
- ii) mood disorders as in claim 47
- iii) schizophrenia and related disorders as in claims 48 and 49
- iv) drug use and dependence as in claim 50
- v) memory loss disorders as in claim 51

The different disorders comprise a diverse spectrum of medical disorders that are unique in terms of their diagnosis, etiology, pathology, and affected populations and therefore the different species do not relate to a general inventive concept under PCT Rule 13.1.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims

subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise require all the limitations of an allowed generic claim. Currently, the following claim(s) are generic: claim 44.

#### REQUIREMENT FOR UNITY OF INVENTION

As provided in 37 CFR 1.475(a), a national stage application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept ("requirement of unity of invention"). Where a group of inventions is claimed in a national stage application, the requirement of unity of invention shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. The expression "special technical features" shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.

The determination whether a group of inventions is so linked as to form a single general inventive concept shall be made without regard to whether the inventions are claimed in separate claims or as alternatives within a single claim. See 37 CFR 1.475(e).

# WHEN CLAIMS ARE DIRECTED TO MULTIPLE CATEGORIES OF INVENTIONS

As provided in 37 CFR 1.475(b), a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories:

- (1) A product and a process specially adapted for the manufacture of said product; or
  - (2) A product and process of use of said product; or
- (3) A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or
- (4) A process and an apparatus or means specifically designed for carrying out the said process; or
- (5) A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process.

Otherwise, unity of invention might not be present. See 37 CFR 1.475(c).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention or species.

Should applicant traverse on the ground that the inventions have unity of invention (37 CFR 1.475(a)), applicant must provide reasons in support thereof.

Applicant may submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case.

Where such evidence or admission is provided by applicant, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 10/582,163 Page 7

Art Unit: 1649

Advisory Information

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to KIMBERLY A. BALLARD whose telephone number is

(571)272-2150. The examiner can normally be reached on Monday-Friday 8:30 AM - 5

PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Jeffrey Stucker can be reached on 571-272-0911. The fax phone number

for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

USPTO Customer Service Representative or access to the automated information

system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Kimberly Ballard

Art Unit 1649

/Elizabeth C. Kemmerer/ Elizabeth C. Kemmerer, Ph.D.

Primary Examiner, Art Unit 1646